Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.89
- Piotroski Score 2.00
- Grade Hold
- Symbol (ZYNE)
- Company Zynerba Pharmaceuticals, Inc.
- Price $1.30
- Changes Percentage (2.36%)
- Change $0.03
- Day Low $1.26
- Day High $1.34
- Year High $1.40
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.79
- Trailing P/E Ratio -1.6455696202532
- Forward P/E Ratio -1.6455696202532
- P/E Growth -1.6455696202532
- Net Income $-34,820,072
Income Statement
Quarterly
Annual
Latest News of ZYNE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity
ROE is a key metric to assess a company's ability to generate returns on shareholder investments. Zynex Inc. has an ROE of 13%, indicating its success in turning equity into profits. However, its high...
By Yahoo! Finance | 1 day ago -
Zynex Inc (ZYXI) Q3 2024 Earnings Call Highlights: Navigating Growth and Challenges
In the third quarter, orders growth decelerated but is expected to maintain double-digit growth in the fourth quarter and into next year. The strategic review process is ongoing, and no share repurcha...
By Yahoo! Finance | 3 weeks ago -
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
To identify a stock with potential for long-term value growth, look for increasing Return on Capital Employed (ROCE) and rising capital employed....
By Yahoo! Finance | 3 months ago
